Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.

Date publication

septembre 2024

Journal

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine

Tous les auteurs :
Bouguen G, Gossec L, Abitbol V, Senbel E, Bonnaud G, Roblin X, Bouhnik Y, Nancey S, Mathieu N, Filippi J, Vuitton L, Nahon S, Dellal A, Denis A, Foulley L, Habauzit C, Benkhalifa S, Marotte H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39322802

Résumé

Biosimilars are cost-effective alternatives to reference products for patients with inflammatory bowel diseases (IBD) and chronic inflammatory rheumatic diseases (CIRD), but patient beliefs can affect adherence to the transition. This study aimed to explore patient experience and satisfaction after switching to CT-P17, a high-concentration (100 mg/mL), citrate-free adalimumab biosimilar.

Référence

BioDrugs. 2024 09 25;: